Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Liabilities and Shareholders Equity (2016 - 2026)

Avanos Medical's Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $1.1 billion for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 6.97% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 billion, a 30.04% decrease, with the full-year FY2025 number at $1.1 billion, down 6.97% from a year prior.
  • Liabilities and Shareholders Equity hit $1.1 billion in Q4 2025 for Avanos Medical, up from $1.1 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AVNS hit a ceiling of $1.8 billion in Q4 2022 and a floor of $1.0 billion in Q2 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $1.5 billion across 5 years, with a median of $1.7 billion in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 11.43% in 2022 and later plummeted 37.33% in 2025.
  • Tracing AVNS's Liabilities and Shareholders Equity over 5 years: stood at $1.6 billion in 2021, then rose by 11.43% to $1.8 billion in 2022, then decreased by 5.29% to $1.7 billion in 2023, then plummeted by 31.8% to $1.2 billion in 2024, then decreased by 6.97% to $1.1 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AVNS at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.